Overview

Evaluate the Efficacy and Safety of Rasburicase (Fasturtec®) in the Prevention and Treatment of Hyperuricemia in Pediatric Patients With Non-Hodgkin's Lymphoma and Acute Leukemia

Status:
Completed

Trial end date:
2021-03-12

Target enrollment:

Participant gender:

Summary

Primary Objective: To evaluate safety of rasburicase in pediatric patients with NHL and AL Secondary Objective: To assess efficacy of rasburicase for prevention and treatment of hyperuricemia

Phase:

Phase 4

Details

Lead Sponsor:

Sanofi

Treatments:

Rasburicase